Astrazeneca (AZN) Assets Average (2009 - 2026)

Astrazeneca's Assets Average history runs 18 years deep, the most recent figure standing at $114.0 billion for Q1 2026.

• In Q1 2026, Assets Average rose 8.47% year-over-year to $114.0 billion; the TTM figure through Mar 2026 stood at $114.0 billion (up 8.47% YoY), while the FY2025 annual figure was $109.1 billion, up 109.02% from the prior year.
• Assets Average was $114.0 billion for Q1 2026 at Astrazeneca, roughly flat from $114.3 billion in the prior quarter.
• In the past five years, Assets Average ranged from a high of $114.3 billion in Q4 2025 to a low of $48.2 billion in Q4 2023.
• Historically, Assets Average has averaged $93.9 billion across 5 years, with a median of $98.4 billion in 2022.
• The sharpest annual moves came in 2023 and 2024: Assets Average plunged 49.44% in 2023, then soared 116.76% in 2024.
• A 5-year view of Assets Average shows it stood at $95.3 billion in 2022, then slumped by 49.44% to $48.2 billion in 2023, then soared by 116.76% to $104.5 billion in 2024, then grew by 9.37% to $114.3 billion in 2025, then dropped by 0.19% to $114.0 billion in 2026.
• The last three Assets Average figures came in at $114.0 billion (Q1 2026), $114.3 billion (Q4 2025), and $113.4 billion (Q3 2025), per Business Quant data.